文献速递毛发、甲与色素性疾病

法国海岸松树皮提取物联合三联乳膏治疗女性面部黄褐斑的双盲随机安慰剂对照试验

French maritime pine bark extract (pycnogenol) in association with triple combination cream for the treatment of facial melasma in women: a double-blind, randomized, placebo-controlled trial.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-09-28

单中心随机双盲安慰剂对照试验纳入44例面部黄褐斑女性,口服75mg海岸松树皮提取物(碧萝芷)或安慰剂每日两次共60天,两组均外用SPF50 PPD17防晒霜及三联乳膏。结果显示口服组mMASI降幅49%(95%CI 36-61%)优于安慰剂组34%(95%CI 16-47%),未发现口服治疗相关不良反应。

要点

  • 口服碧萝芷75mg每日两次可增强防晒霜与三联乳膏治疗面部黄褐斑的疗效
  • 口服组mMASI及色度对比改善均优于安慰剂组,GAIS改善率为86%
  • 试验中未观察到与口服治疗相关的不良反应

核心结论

  • 口服碧萝芷75mg每日两次联合广谱防晒及三联乳膏,对女性面部黄褐斑的疗效优于安慰剂联合方案,且耐受性良好。

主要发现

  • 两组mMASI评分、MELASQoL评分及色度对比均较基线下降(P < 0.01)。
  • mMASI平均降幅(95%CI)为碧萝芷组49%(36-61%)、安慰剂组34%(16-47%)。
  • mMASI降幅与色度对比改善碧萝芷组优于安慰剂组(P < 0.05)。
  • GAIS分析显示改善率碧萝芷组86%(95%CI 68-96%)、安慰剂组55%(95%CI 32-73%)。
  • 未发现与口服治疗相关的不良反应。

关键数值与推荐

  • 口服碧萝芷剂量为75mg,每日两次,疗程60天。
  • 所有患者均使用SPF50、PPD17的着色防晒霜及夜间三联乳膏。
  • 主要结局为mMASI评分较基线的变化,次要结局包括MELASQoL、色度指数与GAIS。

临床怎么用

  • 对接受防晒与三联乳膏治疗的面部黄褐斑女性,可考虑加用口服碧萝芷75mg每日两次以增强疗效。
  • 治疗期间需坚持广谱防晒与夜间三联乳膏基础方案。

局限性

  • 原文摘要未报告局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Melasma can be recalcitrant to treatment, and relapses are common. Pycnogenol has been reported to be effective in treating melasma. OBJECTIVE: To compare the efficacy, safety and tolerability of 75 mg pycnogenol taken orally twice a day vs. a placebo, in association with the triple combination and broad-spectrum sunscreen for the treatment of facial melasma. METHODS: A randomized, double-blind, parallel, placebo-controlled study was conducted on 44 women with facial melasma in a single centre from May 2019 through November 2019. Patients with melasma were randomly assigned to orally take 75 mg pycnogenol (PYC) or a placebo (PLAC) twice a day for 60 days. Both groups also received tinted sunscreen [Sun Protection Factor (SPF) 50; Persistent Pigment Darkening (PPD) 17] for daytime use and a topical triple combination at bedtime. The primary outcome was a change from the baseline Modified Melasma Area Severity Index (mMASI) score. Secondary outcomes were improvements in the patients' quality of life (MELASQoL), colorimetric indices and Global Aesthetic Improvement Scale (GAIS). RESULTS: All participants completed the trial. The mean (SD) age of the participants was 39 (7) years, and 91% were phototypes III-IV. Both groups exhibited a reduction in mMASI scores, MELASQoL scores and colour contrast (P < 0.01). The mean (CI 95%) reductions of the mMASI scores were 49% (36-61%) for PYC and 34% (16-47%) for PLAC. The reductions in mMASI scores and colorimetric contrast were superior for the PYC group (P < 0.05). The analysis of GAIS resulted in an improvement of 86% (CI 95%: 68-96%) for the participants in the PYC group and 55% (CI 95%: 32-73%) for those in the PLAC group. There were no adverse effects related to oral treatment. CONCLUSION: Pycnogenol is well-tolerated and increases the effectiveness of broad-spectrum sunscreen and the triple combination in the treatment of facial melasma in women.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Lima PB, Dias JAF, Esposito ACC, et al. French maritime pine bark extract (pycnogenol) in association with triple combination cream for the treatment of facial melasma in women: a double-blind, randomized, placebo-controlled trial. J Eur Acad Dermatol Venereol. 2020. PMID: 32841433. doi:10.1111/jdv.16896

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。